AnaptysBio is a newly streamlined royalty vehicle whose upside depends on Jemperli’s oncology growth, Sagard cash-flow reversion, and a decisive legal outcome against GSK/Tesaro.
Overview
AnaptysBio has completed its transformation from a traditional biotech into a lean, pure-play royalty company following the spin-off of First Tracks Biotherapeutics. With roughly 10 employees, annual operating expenses capped below $10 million, no pipeline development burn, and royalties tied to GSK’s Jemperli and Vanda’s imsidolimab, ANAB offers unusually high operating leverage. The thesis centers on converting partner-funded commercial growth into shareholder cash returns while avoiding the clinical-trial and financing risks typical of pre-commercial biotech companies.